Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quality of life with recombinant TSH vs thyroid hormone withdrawal in thyroid cancer
2007-002713-39Phase 4Terminated
- Sponsor
- Herlev Hospital
- Start
- Jul 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of thyrotropin alfa in papillary thyroid cancer (PTC) and follicular carcinoma (FTC) (2 arms), sponsored by Herlev Hospital. Primary endpoints: Quality of life by VAS, Quality of life by SF-36 and 1 more. Started Jul 2007; status: terminated.
02
Drugs
thyrotropin alfa
03
Conditions
papillary thyroid cancer (PTC)follicular carcinoma (FTC)
Beyond the preview
Go deeper on 2007-002713-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002713-39.